PPC
SRPT icon

Park Place Capital’s Sarepta Therapeutics SRPT Stock Holding History

Park Place Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$213 – 825
2025
Q2 		$213 Hold
12
– – ﹤0.01% 804
2025
Q1 		$766 Hold
12
– – ﹤0.01% 795
2024
Q4 		$1.46K Hold
12
– – ﹤0.01% 762
2024
Q3 		$1.5K Hold
12
– – ﹤0.01% 801
2024
Q2 		$1.9K Hold
12
– – ﹤0.01% 780
2024
Q1 		$1.55K Buy
+12
New +$1.47K ﹤0.01% 856
2023
Q4 		– Sell
-84
Closed -$10.2K – 1008
2023
Q3 		$10.2K Sell
84
-24
-22% -$2.71K ﹤0.01% 755
2023
Q2 		$12.4K Buy
108
+15
+16% +$1.93K ﹤0.01% 733
2023
Q1 		$12.8K Buy
+93
New +$12.1K ﹤0.01% 719

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Park Place Capital's SRPT Position: Q3 2025 in Review

Park Place Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 12 shares — an estimated $213 sold.

Park Place Capital first reported a position in SRPT in Q1 2023 and held it in 9 quarters. The position peaked at $12.8K in Q1 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Park Place Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Park Place Capital sold 12 Sarepta Therapeutics shares in Q3 2025, an estimated $213.
  • Park Place Capital first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 9 quarters.
  • Park Place Capital's Sarepta Therapeutics position peaked at $12.8K in Q1 2023.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Park Place Capital's 13F filing for Q3 2025, filed 22 Oct 2025.